1. Home
  2. SONM vs EQ Comparison

SONM vs EQ Comparison

Compare SONM & EQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SONM
  • EQ
  • Stock Information
  • Founded
  • SONM 1999
  • EQ 2017
  • Country
  • SONM United States
  • EQ United States
  • Employees
  • SONM N/A
  • EQ N/A
  • Industry
  • SONM Telecommunications Equipment
  • EQ Biotechnology: Pharmaceutical Preparations
  • Sector
  • SONM Telecommunications
  • EQ Health Care
  • Exchange
  • SONM Nasdaq
  • EQ Nasdaq
  • Market Cap
  • SONM 12.6M
  • EQ 13.1M
  • IPO Year
  • SONM 2019
  • EQ 2018
  • Fundamental
  • Price
  • SONM $0.54
  • EQ $1.14
  • Analyst Decision
  • SONM
  • EQ Buy
  • Analyst Count
  • SONM 0
  • EQ 3
  • Target Price
  • SONM N/A
  • EQ $3.00
  • AVG Volume (30 Days)
  • SONM 409.9K
  • EQ 21.8M
  • Earning Date
  • SONM 08-08-2025
  • EQ 08-14-2025
  • Dividend Yield
  • SONM N/A
  • EQ N/A
  • EPS Growth
  • SONM N/A
  • EQ N/A
  • EPS
  • SONM N/A
  • EQ N/A
  • Revenue
  • SONM $57,917,000.00
  • EQ $16,553,000.00
  • Revenue This Year
  • SONM $127.68
  • EQ N/A
  • Revenue Next Year
  • SONM N/A
  • EQ N/A
  • P/E Ratio
  • SONM N/A
  • EQ N/A
  • Revenue Growth
  • SONM N/A
  • EQ N/A
  • 52 Week Low
  • SONM $0.53
  • EQ $0.27
  • 52 Week High
  • SONM $6.38
  • EQ $1.50
  • Technical
  • Relative Strength Index (RSI)
  • SONM 35.10
  • EQ 77.37
  • Support Level
  • SONM $0.54
  • EQ $0.78
  • Resistance Level
  • SONM $0.60
  • EQ $1.25
  • Average True Range (ATR)
  • SONM 0.04
  • EQ 0.23
  • MACD
  • SONM 0.00
  • EQ 0.06
  • Stochastic Oscillator
  • SONM 4.59
  • EQ 77.78

About SONM Sonim Technologies Inc.

Sonim Technologies Inc is a provider of ultra-rugged mobile devices, including phones and accessories designed specifically for task workers physically engaged in their work environments, often in mission-critical roles. The company sells mobile phones, accessories, and solutions to AT&T, T-Mobile, and Verizon in the Canada, and to Bell, Rogers, and Telus and Rogers, Telstra in Australia. The products include rugged mobile phones that can attach to both public and private wireless networks, industrial-grade accessories that meet the requirements of specific applications and software applications, and cloud-based tools that provide management and deployment services to customers. The company generates revenue from discounts, price protection, and customer incentives.

About EQ Equillium Inc.

Equillium Inc is a clinical-stage biotechnology company engaged in developing novel therapeutics to treat severe autoimmune and inflammatory, or immuno-inflammatory, disorders with high unmet medical need. The company intends to commercialize its product candidates either independently or through partnerships, or otherwise monetize its pipeline through strategic transactions. Itolizumab (EQ001), a clinical-stage product candidate, is an anti-CD6 immune-modifying monoclonal antibody, or mAb, that selectively targets the CD6-ALCAM signaling pathway to downregulate pathogenic T effector cells while preserving T regulatory cells critical for maintaining a balanced immune response. The company's other clinical-stage and pre-clinical-stage candidates include EQ101 and EQ302.

Share on Social Networks: